Combined RASSF1A and RASSF2A Promoter Methylation Analysis as Diagnostic Biomarker for Bladder Cancer
Figure 2
RASSF1A and RASSF2A methylation profiles of tumor and normal adjacent tissues. 71% (34/48) of tumor samples had RASSF1A promoter methylation, and 8% (4/48) had RASSF2A promoter methylation. No RASSF4, RASSF5, and RASSF6 promoter methylation were detected.
